MAH0.STU Mereo BioPharma Group plc

Healthcare Biotechnology Stuttgart Exchange
0.2560 EUR
Close of Nov 1, 2026
0.1920 1.92
Market cap
EUR 40.9M
P/E
-
P/B
1.60x
ROE
-95.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is MAH0.STU undervalued?

Graham number

The Graham number of Mereo BioPharma Group plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Mereo BioPharma Group plc fundamental analysis

No fundamental analysis for Mereo BioPharma Group plc yet.

Mereo BioPharma Group plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the …

Full company profile